Skip to content

A COMPREHENSIVE REPORT FOR DECISION MAKING

Oncology DRUG Intelligence

2024

Two Reports providing complete landscape on oncology drug development

RELEASED - JULY 2024

2485

Oncology Drug Discovery Companies Worldwide

Oncology Drug Intelligence (ODI) 2024 is a set of Two Intelligence Reports, which provides Complete Insights to Identify & Connect with Largest Number of Active Oncology Drug Discovery Companies.

oncology Drug intelligence 2024 (Fourteenth Updated Edition)

Report Covers all Aspects of Cancer Drug Development Intelligence

COMPANIES * MOLECULES * INDICATIONS * TECHNOLOGIES * DEALS * FUNDING

Oncology drug intelligence 2024
largest coverage

providing intelligence at fingertips

Countries
1

Worldwide 34 Countries Covered. Largest Coverage Guaranteed

Drug Developers
500

1235 Active Clinical & 1250 Early Stage Oncology Companies Profiled

Unique Molecules in Development
500

Includes – Individual Drug Mechanism of Action & Drug Targets.

Cancer Targets
1 +

Covers complete Emerging Cancer Drug Targets Details with Numerous Technologies

TWO REPORTS

Intelligence @ fingertips

Provides Complete Landscape on Latest Oncology Drug Development covering Emerging Technologies, Partnering and Funding Status in the Domain.
Drug Developers with proper funding, technologies and pipeline are only included.
No Acquired, Merged or Dormant Stage Cancer Targeting Drug Developer is included.

01

identify new opportunities

TWO Oncology reports

360 Degree Insights on Drug Development

  • 2350+ Active Cancer Drug Developers.
  • 4200+ Active Molecules in Development.
  • 1500+ Deals & Partnering Details.
  • Special coverage on CAR-T, Vaccines, ADCs, Monoclonal Antibodies, Oncolytic Viruses and Small molecule Kinase Inhibitors.
  • Emerging Technologies like Microbiome, CRISPER, Exosomes, RNAi etc., as Cancer treatment are covered.

Oncology Clinical Drug Intelligence- 2022

World's Largest Insights based on Active 1150 Clinical Stage Oncology Drug Developers
-----------------------------------------
Includes Insights on
Companies | Technologies
Pipeline | Targets | Deals | Funding

Details

Report provides an extensive coverage on Oncology Drug Development and includes World’s Largest Number of Active Clinical Stage Oncology Drug Developers. (1235 Companies Profiles)

1450+ Pages provides, in-depth Analysis on

  • GLOBAL 1235 CLINICAL STAGE ONCOLOGY DRUG DEVELOPERS.
  • 2730 CANCER TARGETING MOLECULES IN DEVELOPMENT.
  • EMERGING CANCER DRUG TARGETS & PROPERITORY TECHNOLOGIES.
  • ONCOLOGY FOCUSED DEALS & PARTNERING ACTIVITIES.
  • INDIVIDUAL COMPANY FUNDING STATUS

Report opens an immense opportunities to New Business Development.
Explore More

Show

Single Source Solution to Reach-out and connect World’s Largest Number of Active Early Stage Oncology Drug Developers. (1250 Companies).

945 Pages Report contains in-depth Analysis on

  • 1250 ACTIVE COMPANIES PROFILE
  • 1200+ CANCER TARGETING MOLECULES IN DEVELOPMENT.
  • EMERGING CANCER DRUG TARGETS & PROPERITORY TECHNOLOGIES.
  • ONCOLOGY FOCUSED DEALS & PARTNERING ACTIVITIES.
  • INDIVIDUAL COMPANY FUNDING STATUS, and much more. 

Report opens an immense opportunities to New Business Development.
Explore More

Show

Oncology PreClinical Drug Intelligence 2024

World's Largest Insights covering 1250 Active PreClinical Stage Oncology Drug Developers
-----------------------------------------
Includes Insights on
Companies | Technologies
Pipeline | Targets | Deals | Funding

Details

Perfect Solution

Unique first in class Intelligence Report

Comparisons
Oncology Drug Intelligence 2024
Other Intelligence Sources
Clinical Stage Oncology Drug Developers
1235 Active Companies
(Companies with Active Pipeline are only Included)
800-1000 Companies
(may also contains data of dormant, closed, acquired or merged companies)
Pre-Clinical Stage Oncology Drug Developers
1250 Active Companies
(Well Funded with clear defined early stage Pipeline)
400-600 Companies
(includes inactive and other domain companies)
Worldwide Coverage
38 Countries Included
(51% USA, 23% Europe, 21% Asia and 5% ROW)
Mainly focuses on United States & Europe
Oncology Drugs in Development
4700+ Onco Targeting Drugs in Active Development
(2700+ Clinical Stage with NCT Number & 2000+ Preclinical Stage, with their Targets and mechanism of Action)
2000 – 2500 Onco Targeting Drugs
(mainly includes Clinical Stage molecules in development)
Bio-Partnering Details
1700+ Oncology Deals complete Details.
(Complete coverage on Oncology focused Deals, Funding & Partnering Activities, since company’s incorporation)
Limited to Database / Resource Subscribed to.
(Also it may require mapping of events between two or more different resources and filtering Onco Linked Deals).

Free Further Customization is Available on This Report

20% Discount  Till 31 July 2024

Trusted by

BUSINESS LEADERS -WORLDWIDE